ArticleScientific reports2026
Quantitative protein analysis and glycan profiling of umbilical cord plasma and corresponding maternal plasma samples.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Protein glycosylation is an essential post-translational modification boosting proteomic diversity. The major groups of human plasma glycoproteins are immunoglobulins (Igs) and acute-phase proteins (APPs). Changes in plasma Ig and APP levels and their glycosylation have been previously associated with inflammatory diseases, several types of cancer, pregnancy, or aging. In this study, we present a novel approach to investigate the neonatal and maternal plasma at the end of pregnancy using a combination of targeted quantitative proteomics and total plasma N-glycome profiling. We present a new SRM-based multiplex assay to quantify 19 APPs and 7 Igs. We applied this assay to 98 samples of umbilical cord plasma and corresponding maternal plasma samples and observed significantly lower levels of all analyzed proteins in neonates, apart from the glycoprotein alpha-2-macroglobulin. Unlike previous methods, our SRM-MS assay allows us to quantify dozens of proteins simultaneously and to distinguish protein variants. We compared maternal and fetal total plasma-released N-glycomes in the same set of samples. We quantified 66 individual glycans, which were used to calculate 73 glycosylation traits. In neonates, the major N-glycans were di-antennary complex-type with core fucosylation, and the production of higher, branched, sialylated N-glycans was limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.